MCID: OPT008
MIFTS: 38

Optic Nerve Neoplasm

Categories: Cancer diseases, Neuronal diseases, Eye diseases

Aliases & Classifications for Optic Nerve Neoplasm

MalaCards integrated aliases for Optic Nerve Neoplasm:

Name: Optic Nerve Neoplasm 12 15
Optic Nerve Neoplasms 44 73
Tumor of Second Cranial Nerve 12
Neoplasm of Optic Nerve 12
Tumour of Optic Nerve 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3419
MeSH 44 D019574
NCIt 50 C4801
ICD10 33 C72.3
UMLS 73 C0524802

Summaries for Optic Nerve Neoplasm

MalaCards based summary : Optic Nerve Neoplasm, also known as optic nerve neoplasms, is related to neurofibromatosis, familial spinal and scleral staphyloma. An important gene associated with Optic Nerve Neoplasm is NF1 (Neurofibromin 1), and among its related pathways/superpathways are Neuroscience and Glioblastoma Multiforme. The drugs Dacarbazine and Temozolomide have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and spinal cord, and related phenotypes are Increased proliferation and behavior/neurological

Related Diseases for Optic Nerve Neoplasm

Diseases related to Optic Nerve Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 154)
# Related Disease Score Top Affiliating Genes
1 neurofibromatosis, familial spinal 10.9 NF1 NF2
2 scleral staphyloma 10.9 NF1 OPTN
3 malignant glandular tumor of peripheral nerve sheath 10.9 NF1 SYP
4 rhabdoid meningioma 10.8 NF2 SYP
5 neurofibrosarcoma 10.8 NF1 NF2
6 chiari malformation 10.8 MAP2 SYP
7 rosette-forming glioneuronal tumor 10.7 MAP2 SYP
8 malignant peritoneal mesothelioma 10.6 CDKN2A NF2
9 immature cataract 10.6 NF1 NF2
10 lung meningioma 10.6 ENO2 NF2
11 duodenal somatostatinoma 10.6 ENO2 NF1
12 epithelioid malignant peripheral nerve sheath tumor 10.6 ENO2 NF1
13 tanycytic ependymoma 10.6 NES NF2 SYP
14 dysembryoplastic neuroepithelial tumor 10.6 MAP2 NES SYP
15 ureter small cell carcinoma 10.6 ENO2 SYP
16 malignant sertoli cell tumor 10.6 ENO2 SYP
17 meningothelial meningioma 10.6 ENO2 NF2
18 urinary bladder small cell neuroendocrine carcinoma 10.6 ENO2 SYP
19 mucopolysaccharidosis, type iiia 10.5 MAP2 NES
20 auditory system cancer 10.5 ENO2 SYP
21 gliofibroma 10.5 NF1 TP53
22 sinonasal undifferentiated carcinoma 10.5 ENO2 SYP
23 gallbladder small cell carcinoma 10.5 ENO2 SYP
24 conventional leiomyosarcoma 10.5 CDKN2A NF1
25 inverted transitional papilloma 10.5 CDKN2A KRT5
26 pancreatic somatostatinoma 10.5 ENO2 SYP
27 cutaneous ganglioneuroma 10.5 ENO2 SYP
28 small cell carcinoma of the bladder 10.5 ENO2 SYP
29 orbital cancer 10.5 ENO2 SYP
30 ovarian carcinosarcoma 10.5 ENO2 SYP
31 atypical neurofibroma 10.5 CDKN2A NF1 NF2
32 pulmonary large cell neuroendocrine carcinoma 10.5 ENO2 SYP
33 subependymal glioma 10.5 ENO2 SYP
34 plexiform neurofibroma 10.5 NF1 NF2
35 cerebral convexity meningioma 10.5 NF2 TP53
36 olfactory nerve neoplasm 10.5 ENO2 SYP
37 cauda equina neoplasm 10.4 ENO2 SYP
38 cellular ependymoma 10.4 SYP TP53
39 olfactory groove meningioma 10.4 NF2 TP53
40 plexiform schwannoma 10.4 ENO2 NF1 NF2
41 extraosseous chondrosarcoma 10.4 ENO2 SYP
42 nodular prostate 10.4 ENO2 LOX
43 neuroma 10.4 ENO2 NF1 NF2
44 spinal cancer 10.4 NF2 TP53
45 malignant teratoma 10.4 ENO2 SYP
46 benign ependymoma 10.3 ENO2 NF2 SYP
47 papillary tumor of the pineal region 10.3 ENO2 MAP2 SYP
48 malignant spiradenoma 10.3 KRT5 TP53
49 paraganglioma 10.3 ENO2 NF1 SYP
50 pineal gland cancer 10.3 ENO2 SYP

Graphical network of the top 20 diseases related to Optic Nerve Neoplasm:



Diseases related to Optic Nerve Neoplasm

Symptoms & Phenotypes for Optic Nerve Neoplasm

GenomeRNAi Phenotypes related to Optic Nerve Neoplasm according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased proliferation GR00094-A 8.62 NF2 TP53

MGI Mouse Phenotypes related to Optic Nerve Neoplasm:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.18 ACE CDKN2A ENO2 FABP7 KRT5 LOX
2 growth/size/body region MP:0005378 10 ACE CDKN2A ENO2 H2AFX KRT5 MAP2
3 endocrine/exocrine gland MP:0005379 9.92 MIB1 NF1 NF2 TP53 ACE CDKN2A
4 homeostasis/metabolism MP:0005376 9.9 FABP7 H2AFX LOX MIB1 MTO1 NF1
5 craniofacial MP:0005382 9.85 ENO2 KRT5 MIB1 NF1 NF2 TP53
6 mortality/aging MP:0010768 9.73 KRT5 LOX MAP2 MIB1 MTO1 NF1
7 neoplasm MP:0002006 9.1 ACE CDKN2A H2AFX NF1 NF2 TP53

Drugs & Therapeutics for Optic Nerve Neoplasm

Drugs for Optic Nerve Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 92)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dacarbazine Approved, Investigational Phase 3,Phase 1,Phase 2,Early Phase 1 4342-03-4 5351166
2
Temozolomide Approved, Investigational Phase 3,Phase 1,Phase 2,Early Phase 1 85622-93-1 5394
3
Carboplatin Approved Phase 3,Phase 1,Phase 2 41575-94-4 10339178 498142 38904
4 Alkylating Agents Phase 3,Phase 1,Phase 2,Early Phase 1
5 Antineoplastic Agents, Alkylating Phase 3,Phase 1,Phase 2,Early Phase 1
6
Irinotecan Approved, Investigational Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
7
Lenalidomide Approved Phase 2,Phase 1 191732-72-6 216326
8
Oxaliplatin Approved, Investigational Phase 2,Phase 1 61825-94-3 5310940 9887054 43805 6857599
9
Bevacizumab Approved, Investigational Phase 1, Phase 2 216974-75-3
10
Vincristine Approved, Investigational Phase 1, Phase 2 2068-78-2, 57-22-7 5978
11
Piperazine Approved, Vet_approved Phase 1, Phase 2 110-85-0 4837
12
Mebendazole Approved, Vet_approved Phase 1, Phase 2 31431-39-7 4030
13
Peginterferon alfa-2b Approved Phase 2 99210-65-8, 215647-85-1
14
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
15
Citric Acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 77-92-9 311
16
Nicotinamide Approved, Investigational, Nutraceutical Phase 2 98-92-0 936
17
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
18
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
19
tipifarnib Investigational Phase 2 192185-72-1 159324
20
Camptothecin Experimental Phase 2,Phase 1 7689-03-4
21 topoisomerase I inhibitors Phase 2,Phase 1
22 Topoisomerase Inhibitors Phase 2,Phase 1
23 Angiogenesis Inhibitors Phase 1, Phase 2,Phase 2
24 Angiogenesis Modulating Agents Phase 1, Phase 2,Phase 2
25 Anti-Bacterial Agents Phase 2,Phase 1
26 Immunosuppressive Agents Phase 2,Phase 1
27 Anti-Infective Agents Phase 2,Phase 1
28 Protein Kinase Inhibitors Phase 2,Phase 1
29 Antineoplastic Agents, Phytogenic Phase 2,Phase 1
30 interferons Phase 2
31 Anthelmintics Phase 1, Phase 2
32 Piperazine citrate Phase 1, Phase 2
33 Anticonvulsants Phase 1, Phase 2
34 Interferon-alpha Phase 2
35 Antiparasitic Agents Phase 1, Phase 2
36 Antiviral Agents Phase 2
37 Antimitotic Agents Phase 1, Phase 2
38 Micronutrients Phase 2
39 Nicotinic Acids Phase 2
40 Trace Elements Phase 2
41 Vitamin B Complex Phase 2
42 Vitamins Phase 2
43 Citrate Nutraceutical Phase 1, Phase 2
44 Folate Nutraceutical Phase 2
45 Vitamin B3 Nutraceutical Phase 2
46 Grapefruit Seed Extract Nutraceutical Phase 2
47 Vitamin B9 Nutraceutical Phase 2
48
Lenograstim Approved, Investigational Phase 1 135968-09-1
49
Bortezomib Approved, Investigational Phase 1 179324-69-7 387447 93860
50
Vorinostat Approved, Investigational Phase 1 149647-78-9 5311

Interventional clinical trials:

(show all 40)
# Name Status NCT ID Phase Drugs
1 Phase 3 Study of ANP Therapy vs. TMZ for Optic Pathway Glioma Withdrawn NCT01260103 Phase 3 Temozolomide;ANP Therapy
2 Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy Completed NCT00679354 Phase 2 cilengitide
3 Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Completed NCT00091182 Phase 2 oxaliplatin
4 Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma Completed NCT00070525 Phase 2 tipifarnib
5 Irinotecan in Treating Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
6 Antineoplaston Therapy in Treating Children With Visual Pathway Glioma Completed NCT00003477 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
7 Multisession Radiosurgery for Optic Nerve Sheath Meningiomas Recruiting NCT02594709 Phase 2
8 Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma Recruiting NCT02839720 Phase 2 Selumetinib
9 Phase II Pegylated Interferon Recruiting NCT02343224 Phase 2 Pegylated interferon alpha-2b
10 A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas Recruiting NCT01837862 Phase 1, Phase 2 Mebendazole;Vincristine;Carboplatin;Temozolomide;Bevacizumab;Irinotecan
11 Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma Recruiting NCT01089101 Phase 1, Phase 2 Selumetinib
12 Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma Active, not recruiting NCT01553149 Phase 2 Lenalidomide
13 Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours Not yet recruiting NCT03326388 Phase 1, Phase 2 Selumetinib
14 Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas Terminated NCT01338857 Phase 2 Sorafenib (Nexavar)
15 EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome Completed NCT00056199 Phase 1 EYE001
16 Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors Completed NCT01076530 Phase 1 vorinostat;temozolomide
17 Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma Completed NCT00994500 Phase 1 vorinostat;bortezomib
18 ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors Completed NCT00946335 Phase 1 veliparib;temozolomide
19 Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment Completed NCT00929903 Phase 1 pazopanib hydrochloride
20 Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma Completed NCT00363272 Phase 1 ispinesib
21 AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors Completed NCT00326664 Phase 1 Cediranib Maleate
22 Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas Completed NCT00101270 Phase 1 irinotecan hydrochloride;oxaliplatin
23 Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors Completed NCT00100880 Phase 1 lenalidomide
24 Cilengitide in Treating Children With Refractory Primary Brain Tumors Completed NCT00063973 Phase 1 cilengitide
25 FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia Completed NCT00053963 Phase 1 romidepsin
26 Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors Completed NCT00052780 Phase 1 O6-benzylguanine;temozolomide
27 Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas Completed NCT00012181 Phase 1 alvocidib
28 Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors Recruiting NCT02780804 Phase 1 Entinostat
29 Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors Recruiting NCT02372409 Phase 1 Doxorubicin;Etoposide
30 Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors Active, not recruiting NCT02415153 Phase 1 Pomalidomide
31 Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor Active, not recruiting NCT00638898 Phase 1 busulfan;melphalan;topotecan hydrochloride
32 Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia Terminated NCT01088763 Phase 1 gamma-secretase/Notch signalling pathway inhibitor RO4929097;dexamethasone
33 Ophthalmological Screening and Follow-up of Optic Pathway Gliomas in Children With Neurofibromatosis Type 1. Unknown status NCT02078401
34 A Phase II Trial of CyberKnife Radiosurgery to Perioptic Tumors Completed NCT02225197 Not Applicable
35 Natural History Study of Patients With Neurofibromatosis Type I Recruiting NCT00924196
36 PET/MRI in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1) Active, not recruiting NCT01800032
37 Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors Active, not recruiting NCT00919750
38 18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas Terminated NCT02175745 Not Applicable 18F-fluoro-dihydroxyphenylalanine
39 Autologous Stem Cell Collection and Reinfusion in Newly Diagnosed High Grade Gliomas Withdrawn NCT02976441 Early Phase 1 Temozolomide
40 Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors Withdrawn NCT02194452 Not Applicable

Search NIH Clinical Center for Optic Nerve Neoplasm

Cochrane evidence based reviews: optic nerve neoplasms

Genetic Tests for Optic Nerve Neoplasm

Anatomical Context for Optic Nerve Neoplasm

MalaCards organs/tissues related to Optic Nerve Neoplasm:

41
Brain, T Cells, Spinal Cord

Publications for Optic Nerve Neoplasm

Variations for Optic Nerve Neoplasm

Expression for Optic Nerve Neoplasm

Search GEO for disease gene expression data for Optic Nerve Neoplasm.

Pathways for Optic Nerve Neoplasm

Pathways related to Optic Nerve Neoplasm according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.7 ENO2 FABP7 MAP2 NF1 NF2 OPTN
2 11.5 CDKN2A NF1 NF2 TP53
3 11.15 FABP7 MAP2 NES SYP

GO Terms for Optic Nerve Neoplasm

Cellular components related to Optic Nerve Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell body GO:0044297 8.8 FABP7 MAP2 NF2

Biological processes related to Optic Nerve Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of protein kinase activity GO:0006469 9.5 CDKN2A NF1 NF2
2 negative regulation of cell proliferation GO:0008285 9.35 CDKN2A FABP7 NF1 NF2 TP53
3 Ras protein signal transduction GO:0007265 9.33 CDKN2A NF1 TP53
4 replicative senescence GO:0090399 9.26 CDKN2A TP53
5 negative regulation of cell-matrix adhesion GO:0001953 8.8 CDKN2A NF1 NF2

Sources for Optic Nerve Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....